

# Minoo Battiwalla

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/689047/publications.pdf>

Version: 2024-02-01

119  
papers

2,882  
citations

201674

27  
h-index

175258

52  
g-index

122  
all docs

122  
docs citations

122  
times ranked

4482  
citing authors

#	ARTICLE	IF	CITATIONS
1	Survivorship Issues: Practices, Guidelines and Controversies. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy, 2020, , 201-219.	0.0	0
2	Upsetting the apple CARâ€T (chimeric antigen receptor Tâ€cell therapy) â€sustainability mandates USA innovation. British Journal of Haematology, 2020, 190, 851-853.	2.5	11
3	Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant. JAMA Oncology, 2020, 6, 696.	7.1	18
4	Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors. Clinical Hematology International, 2020, 2, 109.	1.7	2
5	Premature coronary artery disease following allogeneic stem cell transplantation: an NHLBI Cohort Study. Bone Marrow Transplantation, 2019, 54, 320-322.	2.4	0
6	Borderline Donor Specific Antibodies Are Safe in Haploidentical Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S204.	2.0	1
7	How Sarah Cannon Blood Cancer Network (SCBCN) Uses Historical Data to Benchmark Survival, Transplant Related Mortality, Engraftment and GVHD for Performance Improvement. Biology of Blood and Marrow Transplantation, 2019, 25, S419.	2.0	0
8	Optimizing Plerixafor Algorithm for Mobilization of Peripheral Blood Stem Cells in Patients with Multiple Myeloma Requiring Tandem Transplants. Biology of Blood and Marrow Transplantation, 2019, 25, S218-S219.	2.0	0
9	Persistence of skewed X-chromosome inactivation in pre-B acute lymphoblastic leukemia of a female ATRX mutation carrier. Blood Advances, 2019, 3, 2627-2631.	5.2	2
10	Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 216-222.	2.0	11
11	Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study. Blood, 2019, 134, 4780-4780.	1.4	0
12	Distinct Biomarker Profiles in Ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 460-466.	2.0	3
13	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Advances, 2018, 2, 933-940.	5.2	27
14	Role of G-CSF after High-Dose Post-Transplantation Cyclophosphamide. Blood, 2018, 132, 3384-3384.	1.4	1
15	Neoantigen Landscape of Relapsed Acute Leukemia Following Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 4595-4595.	1.4	0
16	Reprint of: Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care. Biology of Blood and Marrow Transplantation, 2017, 23, S1-S9.	2.0	9
17	Ex vivo T-cellâ€depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy. Cytotherapy, 2017, 19, 735-743.	0.7	5
18	Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia. Leukemia Research Reports, 2017, 7, 40-44.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	3.5	79
20	Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016. <i>Leukemia Research</i> , 2017, 53, 8-12.	0.8	1
21	Hematologic Malignancy Recurrence in Female Reproductive Tract Seen on Routine Gynecologic Screening [25]. <i>Obstetrics and Gynecology</i> , 2017, 129, 109S-109S.	2.4	0
22	Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombocythemia. <i>Transfusion</i> , 2017, 57, 2136-2139.	1.6	2
23	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 6-9.	2.0	49
24	Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 184-192.	2.0	40
25	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 201-210.	2.0	79
26	Pulmonary Histoplasma Infection After Allogeneic Hematopoietic Stem Cell Transplantation: Case Report and Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx041.	0.9	14
27	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	4.1	45
28	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55
29	Risk Factors for Human Papilloma Virus Reactivation in the Genital Tract of Female Stem Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S26.	2.0	0
30	Fertility Preservation Prior to Myeloablative Allogeneic Peripheral Blood Stem Cell Transplant in Clinical Trials for Hematological Malignancies - Practical Challenges in Transplant Coordination. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S113-S114.	2.0	0
31	When the Minimal Becomes Measurable. <i>Journal of Clinical Oncology</i> , 2016, 34, 2557-2558.	1.6	26
32	Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia. <i>Molecular Therapy</i> , 2016, 24, 1655-1664.	8.2	8
33	Epigenetic landscape of the <i>TERT</i> promoter: a potential biomarker for high risk <i>AML</i> / <i>MDS</i> . <i>British Journal of Haematology</i> , 2016, 175, 427-439.	2.5	25
34	Improved Reproducibility of Gvhd Biomarker Assay- Application of Multiplex Microfluidic Channel System. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S388.	2.0	0
35	CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2016, 24, 815-822.	2.2	6
36	Association of Comprehensive Lipoprotein Profiling with Coronary Artery Disease in Allogeneic Stem Cell Transplant (Allo-SCT) Survivors. <i>Blood</i> , 2016, 128, 828-828.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Safety and Feasibility of Ultra-Low Dose IL-2 As Graft Versus Host Disease Prophylaxis in Haplo-Identical Stem Cell Transplantation- a Proof of Concept Pilot Study. <i>Blood</i> , 2016, 128, 386-386.	1.4	0
38	Blood Stream Infection Is Frequent during Conditioning but Does Not Impact Allogeneic Transplant Outcomes in the Modern Era. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S268.	2.0	0
39	Minor ABO Incompatibility Does Not Impact Non-Relapse Mortality in T-Cell Depleted HLA-Matched Sibling Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S276-S277.	2.0	0
40	Clinical and laboratory predictors impacting allogeneic peripheral blood stem cell mobilization. <i>Cytotherapy</i> , 2015, 17, S66.	0.7	0
41	A Rare Consequence of Chronic Graft Versus Host Disease - Peyronie's Disease. <i>Archives in Cancer Research</i> , 2015, 3, .	0.3	9
42	Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 189-196.	2.4	7
43	Minor ABO Incompatibility Does Not Impact Nonrelapse Mortality in T Cell-Depleted Human Leukocyte Antigen-Matched Sibling Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 954-955.	2.0	1
44	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1589-1596.	2.0	37
45	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1790-1795.	2.0	9
46	Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. <i>Cytotherapy</i> , 2015, 17, 1675-1686.	0.7	31
47	HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1783-1789.	2.0	83
48	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
49	Selective Depletion of Alloreactive Donor T Cells with Adenosine: An Efficient, Scaleable, GMP-Compliant, Low-Cost Method to Prevent Gvhd While Preserving Antiviral and Antileukemic Activity in Haploidentical Stem Cell Transplant. <i>Blood</i> , 2015, 126, 380-380.	1.4	2
50	Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status. <i>Blood</i> , 2015, 126, 1267-1267.	1.4	0
51	T Cell Depleted Allogeneic Stem Cell Transplants for Hematological Malignancies: A 20 Year Experience Shows No Relationship Between Choice of Transplanted T Cell Dose or Delayed T Cell Add-Back on Major Outcomes. <i>Blood</i> , 2015, 126, 2013-2013.	1.4	1
52	Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete AlloHSCT. <i>Blood</i> , 2015, 126, 3212-3212.	1.4	0
53	Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1868-1875.	3.5	19
54	Radiation exposure from diagnostic procedures following allogeneic stem cell transplantation - How much is acceptable?. <i>Hematology</i> , 2014, 19, 275-279.	1.5	5

#	ARTICLE	IF	CITATIONS
55	Recombinant Human Factor VIIa for Alveolar Hemorrhage Following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 969-978.	2.0	37
56	Bone Marrow Mesenchymal Stromal Cells to Treat Complications Following Allogeneic Stem Cell Transplantation. <i>Tissue Engineering - Part B: Reviews</i> , 2014, 20, 211-217.	4.8	18
57	Bone Marrow Mesenchymal Stromal Cells to Treat Tissue Damage in Allogeneic Stem Cell Transplant Recipients: Correlation of Biological Markers with Clinical Responses. <i>Stem Cells</i> , 2014, 32, 1278-1288.	3.2	83
58	Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. <i>Experimental Hematology</i> , 2014, 42, 83-89.	0.4	26
59	The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches. <i>Cytotherapy</i> , 2014, 16, 927-933.	0.7	56
60	Repair of Impaired Pulmonary Function Is Possible in Very-Long-Term Allogeneic Stem Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 209-213.	2.0	13
61	The Clinical and Financial Cost of Preemptive Management of CMV Disease — Implications for Immunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S128.	2.0	0
62	Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. <i>Molecular Therapy</i> , 2014, 22, 1388-1395.	8.2	106
63	Abl(17p) in AML: who will guard the guardian?. <i>Blood</i> , 2014, 123, 2906-2907.	1.4	0
64	Early CMV Reactivation Still Remains a Cause of Increased Transplant Related Mortality in the Current Era: A CIBMTR Analysis. <i>Blood</i> , 2014, 124, 47-47.	1.4	2
65	CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3898-3898.	1.4	0
66	T Cell Exhaustion and Downregulation of Cytotoxic NK Cells — an Immune Escape Mechanism in Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3781-3781.	1.4	11
67	Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2550-2550.	1.4	0
68	A Novel Standardized Quantitative Suppression Assay Reveals a Diversity of Human Immune-Regulatory Cell Potency. <i>Blood</i> , 2014, 124, 316-316.	1.4	0
69	Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant. <i>Haematologica</i> , 2013, 98, 346-352.	3.5	22
70	The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors. <i>Blood</i> , 2013, 121, 4800-4806.	1.4	44
71	Safety Issues in MSC Therapy. , 2013, , 377-387.		1
72	Human herpes 6 virus encephalitis complicating allogeneic hematopoietic stem cell transplantation. <i>Neurology</i> , 2013, 80, 1494-1500.	1.1	78

#	ARTICLE	IF	CITATIONS
73	Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways. <i>Blood</i> , 2013, 122, 3885-3885.	1.4	5
74	Transplantation For Myelodysplastic Syndrome Evolving From Aplastic Anemia Treated With Immunosuppressive Therapy: From The Fred Hutchinson Cancer Research Center and Center For International Bone Marrow Transplantation Research. <i>Blood</i> , 2013, 122, 924-924.	1.4	0
75	Alemtuzumab Achieved Durable Hematologic Response In Heavily Treated T-Large Granular Lymphocytosis Irrespective To STAT3 Mutation Or V-Beta Clone Size. <i>Blood</i> , 2013, 122, 3705-3705.	1.4	1
76	Female Long-Term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation: Evaluation and Management. <i>Seminars in Hematology</i> , 2012, 49, 83-93.	3.4	65
77	HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1302-1308.	2.0	15
78	Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2085-2088.	1.3	6
79	HLA-Matched Sibling Transplantation for Severe Aplastic Anemia: Impact of HLA DR15 Antigen Status on Engraftment, Graft-versus-Host Disease, and Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1401-1406.	2.0	6
80	Mesenchymal Stem Cells in Hematopoietic Stem Cell Transplantation. , 2012, , 101-115.		3
81	T-cell large granular lymphocytosis associated with malignant thymoma. <i>Leukemia Research</i> , 2012, 36, e187-e189.	0.8	0
82	Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?. <i>Blood</i> , 2012, 120, 3283-3283.	1.4	2
83	Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation. <i>Blood</i> , 2011, 117, 5250-5256.	1.4	18
84	HLA-C Antigen Mismatch Is Associated with Worse Outcome in Unrelated Donor Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 885-892.	2.0	196
85	Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1846-1854.	2.0	28
86	Selectively T Cell-Depleted Allografts from HLA-Matched Sibling Donors Followed by Low-Dose Posttransplantation Immunosuppression to Improve Transplantation Outcome in Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1855-1861.	2.0	52
87	Second Stem Cell Transplantation (SCT) for Relapsed Leukemia Provides Only Modest Prolongation of Survival. <i>Blood</i> , 2011, 118, 2001-2001.	1.4	0
88	Relapse after allogeneic stem cell transplantation. <i>Expert Review of Hematology</i> , 2010, 3, 429-441.	2.2	154
89	Multiparameter flow cytometry for the diagnosis and monitoring of small GPIâ€deficient cellular populations. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 348-356.	1.5	22
90	Acute myeloid leukemia and diabetes insipidus with monosomy 7. <i>Cancer Genetics and Cytogenetics</i> , 2009, 190, 97-100.	1.0	22

#	ARTICLE	IF	CITATIONS
91	Immune Deficits in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients. <i>Mycopathologia</i> , 2009, 168, 271-282.	3.1	15
92	A Comparison of Measured Creatinine Clearance versus Calculated Glomerular Filtration Rate for Assessment of Renal Function before Autologous and Allogeneic BMT. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 574-579.	2.0	21
93	Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 887-890.	2.0	1
94	Mesenchymal stem cells in hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2009, 11, 503-515.	0.7	163
95	Modulation of Immune Function. , 2009, , 234-258.		0
96	Novel alternative for treating paroxysmal nocturnal hemoglobinuria in selected patients. <i>Community Oncology</i> , 2008, 5, 70.	0.2	0
97	Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2008, 49, 1494-1500.	1.3	2
98	Impact of Age on Transfusion Independence Response, Survival, and Transformation to Acute Myeloid Leukemia in Patients with Deletion 5q: A Sub-Analysis of the MDS-003 Study. <i>Blood</i> , 2008, 112, 5071-5071.	1.4	2
99	Impact of Baseline Renal Function on Transfusion-Independence Response, Survival, and Transformation to Acute Myeloid Leukemia in Patients with Deletion 5q: A Sub-Analysis of the MDS-003 Study. <i>Blood</i> , 2008, 112, 5088-5088.	1.4	2
100	BuCy Provides Equivalent Outcomes to VCyTBI as Conditioning Prior to Auto-SCT in Patients with Relapsed/Refractory NHL and Is a Valuable Option in Older (≥60 years) Patients.. <i>Blood</i> , 2008, 112, 2176-2176.	1.4	4
101	Clinical and Genetic Factors Underlying Acute Bone Mineral Density Loss by 100 Days after Blood and Marrow Transplantation: A Potential Early Regimen-Related Complication. <i>Blood</i> , 2008, 112, 52-52.	1.4	0
102	Prevention and Early Treatment of Invasive Fungal Infection in Patients with Cancer and Neutropenia and in Stem Cell Transplant Recipients in the Era of Newer Broad-Spectrum Antifungal Agents and Diagnostic Adjuncts. <i>Clinical Infectious Diseases</i> , 2007, 44, 402-409.	5.8	166
103	HLA DR15 and Immunobiologic Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 371.	2.0	2
104	Ganciclovir Inhibits Lymphocyte Proliferation by Impairing DNA Synthesis. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 765-770.	2.0	74
105	Fluorescence Activated Cell Sorting (FACS) Followed by Fluorescence In Situ Hybridization (FISH) To Determine Clonal Origins of Cells in Myelodysplastic Syndrome (MDS) with Paroxysmal Nocturnal Hemoglobinuria (PNH).. <i>Blood</i> , 2007, 110, 4623-4623.	1.4	0
106	Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. <i>Blood</i> , 2006, 107, 1970-1973.	1.4	26
107	Immunotherapy for Fungal Infections. <i>Clinical Infectious Diseases</i> , 2006, 42, 507-515.	5.8	91
108	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. <i>Blood</i> , 2006, 108, 3033-3033.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Influence of Human Leukocyte Antigen Haplotypes on Acute Graft Versus Host Disease Incidence after Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 2887-2887.	1.4	0
110	Glutathione-S-Transferase M1 (GSTM1) and T1 (GSTT1) Single Nucleotide Polymorphisms (SNPs) Predict Regimen-Related Toxicity after Autologous and Allogeneic Blood and Marrow Transplantation (BMT).. Blood, 2006, 108, 47-47.	1.4	0
111	High Frequency and Early Onset of Bone Mineral Density Loss Following Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 2011-2011.	1.4	6
112	Human T Lymphocyte Activation Kinetics for Identifying and Targeting Alloreactive T Cells.. Blood, 2005, 106, 5249-5249.	1.4	0
113	Ganciclovir Suppresses Human T Lymphocyte Proliferation In Vitro.. Blood, 2005, 106, 5378-5378.	1.4	0
114	Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biology of Blood and Marrow Transplantation, 2004, 10, 49-57.	2.0	56
115	Autoimmune Disease (AD) in Patients with Myelodysplastic Syndrome (MDS): A Retrospective Single Institution Study.. Blood, 2004, 104, 4736-4736.	1.4	0
116	Clinical and Pathological Presentation of T-Cell Large Granular Lymphocyte Proliferations (T-LGL): A Single Institution Experience.. Blood, 2004, 104, 3865-3865.	1.4	7
117	Immunosuppression for Myelodysplastic Syndrome: Association between a Score Based on Presenting Features and Long-Term Survival.. Blood, 2004, 104, 1431-1431.	1.4	0
118	HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. British Journal of Haematology, 2003, 123, 449-453.	2.5	54
119	Allogeneic transplantation using non-myeloablative transplant regimens. Best Practice and Research in Clinical Haematology, 2001, 14, 701-722.	1.7	13